8-K: BIO-key Gets Nasdaq Bid Price Compliance Extension

BIO-key International, Inc. received an additional 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement, pushing the deadline to May 4, 2026.

Summary

• BIO-key International, Inc. (BKYI) failed to regain compliance with Nasdaq's minimum bid price rule of $1.00 per share, as previously reported on May 9, 2025.
• Nasdaq granted the company an additional 180-day period, extending the compliance deadline to May 4, 2026.
• This extension was based on the company meeting other continued listing requirements, including market value of publicly held shares, and its stated intention to cure the deficiency.
• To regain compliance, the common stock's closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days.
• The company plans to monitor its stock price and will consider a reverse stock split if necessary to meet the requirement.
• Failure to comply by May 4, 2026, could lead to delisting, with an opportunity to appeal.

Sentiment

Score: 4

Explanation: While the company failed to meet the initial compliance deadline, the extension from Nasdaq provides a crucial lifeline and time to implement a reverse stock split. The situation remains precarious due to the underlying bid price issue, but the immediate threat of delisting has been deferred.

Positives

• Nasdaq granted an additional 180-day compliance period until May 4, 2026, deferring the immediate threat of delisting.
• The company meets other Nasdaq continued listing requirements, including market value of publicly held shares.
• The company has a clear plan to regain compliance, including the potential for a reverse stock split.

Negatives

• The company failed to regain compliance with Nasdaq's minimum $1.00 bid price rule within the initial compliance period.
• Continued non-compliance could lead to delisting from the Nasdaq Capital Market.

Risks

• Potential delisting of common stock from the Nasdaq Capital Market if the minimum bid price requirement is not met by May 4, 2026.
• The need to effect a reverse stock split, which can sometimes be perceived negatively by investors and may not guarantee sustained compliance.

Future Outlook

The company intends to monitor the closing bid price of its common stock and, if necessary to maintain its Nasdaq listing, will effect a reverse stock split during the second 180-day compliance period.

Management Comments

• The company intends to monitor the closing bid price of its common stock and if required to maintain the listing of its common stock on Nasdaq Capital Market, effect a reverse stock split during this second 180-day compliance period.

Industry Context

Companies, particularly smaller cap technology firms, occasionally face challenges in maintaining minimum bid price requirements on major exchanges like Nasdaq, especially during periods of market volatility or specific company performance issues. Reverse stock splits are a common strategy employed to address such deficiencies and avoid delisting, though they do not fundamentally change a company's market capitalization.

Comparison to Industry Standards

• Nasdaq Listing Rule 5550(a)(2) requires a minimum bid price of $1.00 per share, a standard applied to all listed companies.
• The granting of a second 180-day compliance period is a standard procedure by Nasdaq for companies that meet other listing criteria and demonstrate an intent to cure the deficiency.
• The company's plan to consider a reverse stock split is a common and accepted method for companies to meet bid price requirements, as seen with numerous other companies facing similar delisting threats.

Stakeholder Impact

• Shareholders: Face continued uncertainty regarding the stock's listing status and potential changes in share count due to a reverse stock split. The stock price volatility may continue.
• Employees: No direct impact mentioned, but delisting could affect company morale and future prospects.
• Customers/Suppliers/Creditors: No direct impact mentioned, but delisting could indirectly affect the company's reputation and access to capital, potentially impacting business operations.

Next Steps

• Monitor the closing bid price of common stock.
• Effect a reverse stock split if required to maintain Nasdaq listing during the second 180-day compliance period.
• Regain compliance by achieving a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
• Potentially appeal a delisting determination to a Nasdaq Listing Qualifications Panel if compliance is not demonstrated by May 4, 2026.

Key Dates

Recommendation

The company failed to meet the initial Nasdaq bid price requirement, which is a negative signal. However, the extension provides a temporary reprieve and a clear path (reverse stock split) to regain compliance. The stock remains speculative due to the underlying issue, but the immediate delisting threat is mitigated, warranting a 'hold' for existing investors to observe the outcome of the compliance period and the potential reverse stock split. New investors should approach with caution.

Keywords

BIO-key International, BKYI, Nasdaq, delisting, bid price rule, compliance extension, reverse stock split, SEC filing, 8-K